The results were paradigm-shifting. Rather than only slowing decline, the Precision Medicine group showed measurable improvements in cognitive testing, memory, executive function, processing speed, symptoms, and overall health. For patients and families who have been told that decline can only be monitored or modestly slowed, EVANTHEA offers a very different and more hopeful message.

At The Carroll Institute, we believe this study reinforces a central principle of the Carroll Cognitive Method™: cognitive decline is often a systems problem, and it deserves a systems-based solution.

Why This Study Matters

If you have noticed changes in memory, word-finding, focus, processing speed, or mental clarity, you have probably encountered conflicting explanations. One source may tell you Alzheimer’s disease is mainly about amyloid plaques. Another may focus on inflammation. Others may mention insulin resistance, genetics, toxins, hormones, sleep, or vascular health.

The EVANTHEA Study helps clarify why all of those conversations may matter. Cognitive decline rarely comes from one isolated factor. Instead, many patients appear to have several contributors interacting at the same time.

That insight matters because it changes the clinical question. Rather than asking only, “Which drug matches this diagnosis?” Precision Medicine asks, “What factors are affecting this person’s brain, and how many of them can we improve?”

This shift is important. For years, many families were told to watch, wait, and prepare for decline. However, EVANTHEA provides randomized controlled trial evidence that a more active, personalized, multi-factor approach can produce measurable improvement in selected patients with MCI and early Alzheimer’s disease.

The Limits of the Amyloid-Only Model

For decades, Alzheimer’s research focused heavily on amyloid plaques. The theory was straightforward: if amyloid contributes to Alzheimer’s disease, then removing amyloid should improve outcomes.

However, the results have been disappointing for patients and families looking for true recovery of function. Some amyloid-targeting treatments have slowed decline in certain patients, but slowing decline is not the same thing as improving memory, restoring daily function, or reversing cognitive loss.

EVANTHEA challenged the assumption that Alzheimer’s disease should be approached primarily as a single-target problem. In fact, the study authors noted that previous single-modality trials often targeted one drug, procedure, or pathway that may not reflect the primary drivers of decline in each individual patient.

In other words, amyloid may be part of the picture, but it is not the whole story for many people. That is why a Precision Medicine approach looks more broadly at the biological terrain affecting the brain.

What the EVANTHEA Study Actually Tested

The EVANTHEA Study was a randomized controlled trial involving people with Mild Cognitive Impairment or early dementia due to Alzheimer’s disease. Participants were assigned either to standard-of-care treatment or to a personalized Precision Medicine protocol.

Instead of giving every participant the same treatment, researchers evaluated each person for multiple contributors that may affect brain health. These included inflammation, chronic infection, gut dysbiosis, immune dysfunction, insulin resistance, vascular disease, nocturnal hypoxemia, hormone insufficiency or dysregulation, nutrient deficiencies, toxin exposure, genetic findings, epigenetic markers, and Alzheimer’s-associated biomarkers.

In addition, participants received brain MRI testing with volumetrics at the beginning and end of the study. Cognitive and clinical symptoms were assessed over the course of the trial.

This design matters because it more closely reflects how complex chronic illness behaves in real life. Most patients do not have only one issue affecting the brain. Therefore, a one-size-fits-all approach misses important opportunities for intervention.

What the Study Found

The results were significant. Compared with standard care, the Precision Medicine group showed statistically significant improvements in broad neurocognitive functioning, memory, executive function, processing speed, cognitive symptom severity, and Alzheimer’s disease symptom severity.

In addition, participants showed improvements in overall health markers, including blood pressure, body mass index, glycemic measures, lipid profiles, and methylation status. This is important because brain health does not exist separately from the rest of the body.

Perhaps most importantly, the study reported cognitive improvement rather than simply a slower rate of decline in many participants. That distinction is enormous.

Slowing decline means the downward slope continues, but at a reduced pace. Improvement means patients move in the opposite direction on objective measures. For families living with the fear of Alzheimer’s disease, that difference changes the entire conversation.

Why EVANTHEA Represents a Paradigm Shift

The phrase “paradigm shift” is often overused in healthcare. However, EVANTHEA deserves that description because it challenges several assumptions that have shaped Alzheimer’s care for decades.

For years, the dominant question in Alzheimer’s research was: How do we slow decline?

Most interventions were evaluated based on whether they reduced the rate at which patients worsened. While slowing decline can be meaningful, it is not the same thing as helping patients regain lost function.

EVANTHEA asked a different question: Can patients improve?

That distinction changes everything.

Rather than focusing on a single target such as amyloid plaque, researchers addressed multiple contributors simultaneously through a personalized Precision Medicine framework. The result was not simply a slower decline. For the first time many participants demonstrated measurable improvement in cognitive performance, daily function, and symptom severity.

To understand why this matters, imagine two patients. The first patient declines by two points per year on cognitive testing instead of four. That is an improvement in trajectory, but the patient is still moving in the wrong direction.

The second patient improves on cognitive testing after treatment. That patient is moving in the opposite direction.

Those outcomes are fundamentally different.

This is why EVANTHEA has attracted so much attention among clinicians focused on cognitive health. It is one of the first randomized controlled trials to demonstrate that a comprehensive Precision Medicine approach can produce measurable cognitive improvement in individuals with Mild Cognitive Impairment and early Alzheimer’s disease.

The study does not suggest that every patient will respond the same way. It does not claim that Alzheimer’s disease has been cured.

What it does suggest is equally important: the long-standing assumption that cognitive decline can only be monitored or slowed may no longer be sufficient.

For patients and families facing cognitive decline, that realization changes the entire conversation.

Why Precision Medicine Performed Differently

Precision Medicine performed differently because it did not assume every patient had the same problem.

Consider a patient with poor sleep, insulin resistance, chronic inflammation, hormone deficiencies, vascular issues, and toxin exposure. If care addresses only one factor, the remaining contributors may continue affecting the brain.

By contrast, Precision Medicine asks which factors are present in this particular patient and which ones may be most important to address. As a result, the intervention becomes personalized rather than generic.

This is also why EVANTHEA matters so much. It did not merely suggest that lifestyle matters. It tested a comprehensive, personalized intervention against standard care and showed measurable improvement in multiple cognitive and health outcomes.

What Patients Should Understand About Reversal

Many patients hear the word “reversal” and immediately wonder what it means.

In clinical practice, reversal does not mean perfection. It does not mean every symptom disappears. It does not mean every patient returns to the cognitive abilities they had decades earlier.

Instead, reversal means that objective measures improve after treatment.

That distinction matters because objective improvement can be measured. When a patient performs better on validated cognitive testing after treatment than they did before treatment, that represents improvement rather than continued decline.

For decades, most Alzheimer’s research focused on slowing deterioration. EVANTHEA demonstrated something different: participants improved on cognitive testing following a personalized Precision Medicine intervention.

At The Carroll Institute, we routinely monitor cognitive performance throughout care. In our clinical experience, patients who consistently follow their personalized program demonstrate measurable improvement over time. While individual results vary and no outcome can be guaranteed, improvement is often more achievable than many patients have been led to believe.

This perspective is one of the reasons the EVANTHEA findings are so important. They support a growing body of evidence suggesting that cognitive decline should not always be viewed as a one-way process.

For the right patient, under the right circumstances, meaningful improvement is possible.

How EVANTHEA Relates to the Carroll Cognitive Method™

At The Carroll Institute, the EVANTHEA findings strongly align with the principles behind the Carroll Cognitive Method™.

Precision Medicine helps us ask why a particular brain is struggling. Functional Medicine helps us investigate and address the root causes affecting brain health. Functional Neurology helps us evaluate how well the brain is functioning and support neuroplasticity-based rehabilitation.

This final piece matters. Identifying root causes is essential, but many patients also need help rebuilding function. The brain may need targeted stimulation, repetition, and rehabilitation to strengthen underperforming networks.

Therefore, the Carroll Cognitive Method™ does not stop at testing. It integrates root-cause investigation with functional brain rehabilitation. That is what makes it different from approaches that focus only on diagnosis, only on lifestyle, or only on cognitive exercises.

Why Earlier Evaluation Matters

One of the clearest lessons from Precision Medicine research and clinical experience is that timing matters.

When symptoms first appear, many people dismiss them as normal aging. Others feel reassured when basic testing looks normal. Meanwhile, contributors such as inflammation, insulin resistance, poor sleep, vascular dysfunction, hormone imbalance, or toxin exposure may continue affecting the brain.

Earlier evaluation may create more opportunities because the brain often has greater capacity for adaptation before decline becomes advanced. This does not mean every patient will respond the same way. However, waiting rarely creates more options.

If someone is noticing memory loss, brain fog, word-finding problems, slower thinking, or difficulty keeping up with daily life, the better question is not whether to wait. The better question is what may be driving those changes.

Who Should Pay Attention to EVANTHEA?

The EVANTHEA Study is especially relevant for individuals with Mild Cognitive Impairment, early Alzheimer’s disease, persistent brain fog, increasing forgetfulness, or a strong family history of dementia.

It is also relevant for people who have been told their symptoms are “just aging” but know that something has changed. In many cases, cognitive symptoms appear before a person receives a clear diagnosis. That early window may be an important time to investigate.

At the same time, patients should maintain realistic expectations. EVANTHEA does not prove that every case of Alzheimer’s disease can be reversed. It does, however, provide strong evidence that a personalized, systems-based Precision Medicine approach can produce measurable improvement in selected patients with MCI and early Alzheimer’s disease.

Next Steps

The biggest takeaway from the EVANTHEA Study is not that there is one simple solution for Alzheimer’s disease. The takeaway is that a personalized approach matters.

For decades, many families were told that cognitive decline could only be monitored or modestly slowed. EVANTHEA changed that conversation by showing that measurable improvement is possible when multiple contributors are identified and addressed together.

At The Carroll Institute, we use these same Precision Medicine principles as part of the Carroll Cognitive Method™ to help patients better understand what may be affecting their brain health. If you are in Sarasota, the Gulf Coast region, or looking for a deeper evaluation of memory loss, brain fog, or cognitive performance, Book a discovery call to see if this is a fit for you. Or learn more about our Carroll Cognitive Method™ and ReCODE program.

Sources & Citations

• Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled Trial – Preprints.org
• ReCODE-Based Precision Medicine Framework – The Carroll Institute
• The Carroll Institute Precision Medicine Program Overview – The Carroll Institute
• Brain Health And Cognitive Decline Resources – National Institute on Aging
• Alzheimer’s Disease And Mild Cognitive Impairment Information – Alzheimer’s Association

Medically reviewed by Dr. Garland Glenn, DC, PhD, IFM, AFMC

Last updated: June 8, 2026

This content is for educational purposes and does not substitute personalized medical advice.